Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAIN: CWI with Ropivacaine after Laparoscopy
NCT03645304Unknown
- Sponsor
- Kangbuk Samsung Hospital
- Start
- Jan 2019
- Primary completion
- Apr 2020
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Randomised, double-blind trial of ropivacaine hydrochloride liposomal suspension injection in postoperative pain (2 arms), sponsored by Kangbuk Samsung Hospital. Primary endpoint: Postoperative pain at 24 hours. Status: unknown.
02
Drugs
ropivacaine hydrochloride liposomal suspension injection
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT03645304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03645304.